Strategic Licensing and Partnership: Cizzle Bio Inc.

NewsCollaborations and Partnerships
Written By Cizzle Bio, Inc.

Major North American Expansion

Cizzle Biotechnology Holdings plc has signed a non-binding Memorandum of Understanding (MoU) for an exclusive licensing agreement to develop and market the CIZ1B biomarker test for early-stage lung cancer in the USA and Canada. This partnership, through the newly established Cizzle Bio Inc., will fully fund the development, clinical trials, and commercialization efforts, providing significant financial benefits and cost savings for Cizzle Biotechnology.

Key Highlights:

  • Exclusive license for CIZ1B test in North America.

  • Upfront payment of $100,000 and minimum advance royalty payments of $2.3 million over 30 months.

  • Establishment of Cizzle Bio Inc. to drive US market efforts.

For more details, read the full announcement on Cizzle Biotechnology's website.

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Previous

ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection
Next

Major Step Forward in Cizzle Biotechnology's Programme with Bio-Techne